[1] Sakamoto KM, Grant S, Saleiro D, et al. Targeting novel signaling pathways for resistant acute myeloid leukemia[J]. Mol Genet Metab, 2015, 114(3):397-402.
[2] Annesley CE, Brown P. Novel agents for the treatment of childhood acute leukemia[J]. Ther Adv Hematol, 2015, 6(2):61-79.
[3] Wu H, Wang A, Qi Z, et al. Discovery of a highly potent FLT3 kinase inhibitor for FLT3-ITD-positive AML[J]. Leukemia, 2016, 30(10):2112-2116.
[4] Dany M, Gencer S, Nganga R, et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML[J]. Blood, 2016, 128(15):1944-1958.
[5] Bernasconi P, Boni M, Cavigliano PM, et al. Molecularly targeted therapy in acute myeloid leukemia[J]. Ann N Y Acad Sci, 2016, 1028(6):409-422.
[6] Dombret H, Gardin C. An update of current treatments for adult acute myeloid leukemia[J]. Blood, 2016, 127(1):53-61.
[7] Stein EM. Molecularly targeted therapies for acute myeloid leukemia[J]. Hematology Am Soc Hematol Educ Program, 2015, 2015(1):579-583.
[8] Cooper TM, Cassar J, Eckroth E, et al. A phase I study of quizartinib combined with chemotherapy in relapsed childhood leukemia:a therapeutic advances in childhood leukemia & lymphoma (TACL) study[J]. Clin Cancer Res, 2016, 22(16):4014-4022.
[9] Kadia TM, Ravandi F, Cortes J, et al. New drugs in acute myeloid leukemia[J]. Ann Onco, 2016, 27(5):770-778.
[10] Lee LY, Hernandez D, Rajkhowa T, et al. Preclinical studies of gilteritinib, a next-generation FLT3 inhibitor[J]. Blood, 2017, 129(2):257-260.
[11] Yamada A, Moritake H, Kinoshita M, et al. Relapsed childhood acute myeloid leukemia patient with inversion of chromosome 16 harboring a low FLT3 internal tandem duplication allelic burden and KIT mutations[J]. Pediatr Int, 2016, 58(9):905-908.
[12] Lin PH, Li HY, Fan SC, et al. A targeted next-generation sequencing in the molecular risk stratification of adult acute myeloid leukemia:implications for clinical practice[J]. Cancer Med, 2017, 6(2):349-360.
[13] Kolb EA, Meshinchi S. Acute myeloid leukemia in children and adolescents:identifcation of new molecular targets brings promise of new therapies[J]. Hematol, 2015, 2015(1):507-513.
[14] DiNardo CD, Cortes JE. New treatment for acute myelogenous leukemia[J]. Expert Opinion Pharmacother, 2015, 16(1):95-106.
[15] Chen WC, Yuan JS, Xing Y, et al. An integrated analysis of heterogeneous drug responses in acute myeloid leukemia that enables the discovery of predictive biomarkers[J]. Cancer Res, 2016, 76(5):1214-1224.
[16] Gjertsen BT, Schöffski P. Discovery and development of the Polo-like kinase inhibitor volasertib in cancer therapy[J]. Leukemia, 2015, 29(1):11-19.
[17] Helmke C, Becker S, Strebhardt K. The role of Plk3 in oncogenesis[J]. Oncogene, 2016, 35(2):135-147.
[18] Durlacher CT, Li ZL, Chen XW, et al. An update on the pharmacokinetics and pharmacodynamics of alisertib, a selective Aurora kinase A inhibitor[J]. Clin Exp Pharmacol Physiol, 2016, 43(6):585-601.
[19] Fathi AT, Wander SA, Blonquist TM, et al. Phase I study of the aurora A kinase inhibitor alisertib with induction chemotherapy in patients with acute myeloid leukemia[J]. Haematologica, 2017, 102(4):719-727.
[20] Csizmar CM, Kim D, Sachs Z. The role of the proteasome in AML[J]. Blood Cancer J, 2016, 6(12):e503.
[21] Aplenc R, Meshinchi S, Sung L, et al. The addition of bortezomib to standard chemotherapy for pediatric acute myeloid leukemia has increased toxicity without therapeutic beneft:a report from the Children's Oncology Group[J]. Blood, 2016, 128(22):899.
[22] Larrue C, Saland E, Boutzen H, et al. Proteasome inhibitors induce FLT3-ITD degradation through autophagy in AML cells[J]. Blood, 2016, 127(7):882-892.
[23] Wartman LD, Fiala MA, Fletcher T, et al. A phase I study of carflzomib for relapsed or refractory acute myeloid and acute lymphoblastic leukemia[J]. Leuk Lymphoma, 2016, 57(3):728-730.
[24] Yen CY, Huang HW, Shu CW, et al. DNA methylation, histone acetylation and methylation of epigenetic modifications as a therapeutic approach for cancers[J]. Cancer Lett, 2016, 373(2):185-192.
[25] Falini B, Sportoletti P, Brunetti L, et al. Perspectives for therapeutic targeting of gene mutations in acute myeloid leukaemia with normal cytogenetics[J]. Br J Haematol, 2015, 170(3):305-322.
[26] Gill H, Man C, Ip AH, et al. Azacitidine as post-remission consolidation for sorafenib-induced remission of Fms-like tyrosine kinase-3 internal tandem duplication positive acute myeloid leukemia[J]. Haematologica, 2015, 100(7):e250-e253.
[27] Blum W, Sanford BL, Klisovic R, et al. Maintenance therapy with decitabine in younger adults with acute myeloid leukemia in first remission:a phase 2 Cancer and Leukemia Group B Study (CALGB 10503)[J]. Leukemia, 2017, 31(1):34-39.
[28] Nebbioso A, Benedetti R, Conte M, et al. Genetic mutations in epigenetic modifers as therapeutic targets in acute myeloid leukemia[J]. Expert Opin Ther Targets, 2015, 19(9):1187-1202.
[29] Wouters BJ, Delwel R. Epigenetics and approaches to targeted epigenetic therapy in acute myeloid leukemia[J]. Blood, 2016, 127(1):42-52.
[30] Tsai CT, So CW. Epigenetic therapies by targeting aberrant histone methylome in AML:molecular mechanisms, current preclinical and clinical development[J]. Oncogene, 2016, 36(13):1753-1759.
[31] Morera L, Lübbert M, Jung M. Ta rgeting histone methyltransferases and demethylases in clinical trials for cancer therapy[J]. Clin Epigenetics, 2016, 8(1):57.
[32] Cheng Y, Jia M, Chen Y, et al. Re-evaluation of various molecular targets located on CD34⁺CD38^-Lin^- leukemia stem cells and other cell subsets in pediatric acute myeloid leukemia[J]. Oncol Let, 2016, 11(1):891-897.
[33] Tarlock K, Alonzo TA, Gerbing RB, et al. Gemtuzumab ozogamicin reduces relapse risk in FLT3/ITD acute myeloid leukemia:a report from the Children's Oncology Group[J]. Clin Cancer Res, 2016, 22(8):1951-1957.
[34] Olombel G, Guerin E, Guy J, et al. The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia[J]. Blood, 2016, 127(17):2157-2160.
[35] Pollard JA, Loken M, Gerbing RB, et al. CD33 expression and its association with gemtuzumab ozogamicin response:results from the randomized phase Ⅲ Children's Oncology Group trial AAML0531[J]. J Clin Oncol, 2016, 34(7):747-755.
[36] Rashidi A, Walter RB. Antigen-specific immunotherapy for acute myeloid leukemia:where are we now, and where do we go from here[J]. Exp Rev Hematol, 2016, 9(4):335-350.
[37] Reusch U, Harrington KH, Gudgeon CJ, et al. Characterization of CD33/CD3 tetravalent bispecifc tandem diabodies (TandAbs) for the treatment of acute myeloid leukemia[J]. Clin Cancer Res, 2016, 22(23):5829-5838.
[38] Harrington KH, Gudgeon CJ, Laszlo GS, et al. The broad antiAML activity of the CD33/CD3 BiTE antibody construct, AMG 330, is impacted by disease stage and risk[J]. PLoS One, 2015, 10(8):e135945.
[39] Al-Hussaini M, Rettig MP, Ritchey JK, et al. Targeting CD123 in acute myeloid leukemia using a T-cell-directed dual-affnity retargeting platform[J]. Blood, 2016, 127(1):122-131.
[40] Chien CD, Sauter CT, Ishii K, et al. Preclinical development of FLT3-redirected chimeric antigen receptor T cell immunotherapy for acute myeloid leukemia[J]. Blood, 2016, 128(22):1072.
[41] Krupka C, Kufer P, Kischel R, et al. Blockade of the PD-1/PD-L1 axis augments lysis of AML cells by the CD33/CD3 BiTE antibody construct AMG 330:reversing a T-cell-induced immune escape mechanism[J]. Leukemia, 2016, 30(2):484-491.
[42] Wei A, Tan P, Perruzza S, et al. Maintenance lenalidomide in combination with 5-azacitidine as post-remission therapy for acute myeloid leukaemia[J]. Br J Haematol, 2015, 169(2):199-210.
[43] Turtle CJ, Hanafi LA, Berger C, et al. CD19 CAR-T cells of defned CD4⁺:CD8⁺ composition in adult B cell ALL patients[J]. J Clin Invest, 2016, 126(6):2123-2138.